{"nctId":"NCT00865202","briefTitle":"A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium","startDateStruct":{"date":"2008-12"},"conditions":["Post-operative Delirium"],"count":301,"armGroups":[{"label":"L-Tryptophan","type":"EXPERIMENTAL","interventionNames":["Drug: L-tryptophan supplementation"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: L-tryptophan supplementation","Drug: placebo"]}],"interventions":[{"name":"L-tryptophan supplementation","otherNames":["L-tryptophan 1 gm PO TID starting the evening of surgery"]},{"name":"placebo","otherNames":["Similar appearing placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Included subjects will be 60 years and older undergoing an operation with a planned ICU admission post-operatively.\n\nExclusion Criteria:\n\n* Medications that, when combined with tryptophan, increase the risk of serotonin syndrome. The classes of medications include:\n\n  * monoamine oxidase inhibitors\n  * selective serotonin reuptake inhibitors\n  * serotonin-norepinephrine reuptake inhibitors\n  * triptans\n  * opioids\n  * central nervous system stimulants\n  * bupropion\n  * St. John's Wort\n* Patients who undergo an operation on their brain.\n* Factors which prevent delirium assessment with the CAM-ICU: vision impairment or non-fluent English speakers.\n* A lowered seizure threshold including:\n\n  * history of seizure disorder\n  * alcohol abuse defined by a high AUDIT score (\\>8 females and \\>13 males)\n  * benzodiazepine or barbiturate abuse within three months of the study\n  * OR a positive urine toxicology screen for alcohol, benzodiazepines or barbiturates.\n* Significant liver disease (Child's class B or greater) or significant renal disease (Creatinine ≥2.0).\n* History of Huntington's or Addison's disease. (As requested by the FDA)\n* History of bipolar disorder or a psychotic disorder (such as a psychotic major depression, schizophrenia, schizoaffective disorder, or psychosis in Alzheimer's disease or other dementia). (As requested by the FDA)\n* Women who are not post-menopausal. (As requested by the FDA)","healthyVolunteers":false,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Duration of Post-operative Delirium","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"1.7"},{"groupId":"OG001","value":"3.1","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Incidence of Post-operative Delirium","description":"The incidence and/or duration of excitatory (hyperactive and mixed) post-operative delirium, diagnosed by the Confusion Assessment Method-ICU (CAM-ICU) with the Richmond Agitation Sedation Score (RASS), will be reduced with enteral L-tryptophan supplementation (1 gm TID for the first 3 post-op days), compared to placebo, in older patients (≥ 60 years) undergoing operations requiring ICU admission.\n\nThe incidence and/or duration of all types of post-operative delirium, diagnosed by the CAM-ICU with the RASS, will be reduced with enteral L-tryptophan supplementation (1 gm TID for the first 3 post-op days), compared to placebo, in older patients (≥ 60 years) undergoing operations requiring ICU admission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Level of Post-operative Serum Tryptophan","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":"26"},{"groupId":"OG001","value":"41","spread":"15"}]}]}]},{"type":"SECONDARY","title":"Level of Post-operative Melatonin","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":"31"},{"groupId":"OG001","value":"19","spread":"41"}]}]}]},{"type":"SECONDARY","title":"Length of Post-operative ICU and Hospital Stay","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":"8.4"},{"groupId":"OG001","value":"9.7","spread":"8.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":152},"commonTop":[]}}}